Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Ascletis Pharma, Inc. ( (HK:1672) ) is now available.
Ascletis Pharma Inc. announced promising results from its Phase Ib studies of ASC30, both as an oral tablet and a subcutaneous injection, along with a preclinical study of a combination therapy involving ASC31 and ASC47. The oral tablet showed up to a 6.5% placebo-adjusted mean body weight reduction, with mild-to-moderate gastrointestinal adverse events, while the injection demonstrated an extended half-life supporting monthly and quarterly dosing schedules. These findings highlight the efficacy and safety of Ascletis’ obesity treatments and reinforce the company’s competitive positioning in the obesity drug market.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$12.84 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development of innovative drugs. The company is involved in the pharmaceutical industry, with a primary focus on developing treatments for obesity and related conditions. Ascletis leverages proprietary technologies such as Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) to advance its diverse pipeline of obesity treatments.
Average Trading Volume: 9,139,231
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.8B
For detailed information about 1672 stock, go to TipRanks’ Stock Analysis page.